LOUISVILLE, Colo., Dec. 16, 2019 /PRNewswire/ --French Transit, LLC brands MyChelle Dermaceuticalsand CRYSTAL Deodoranttoday announced plans to continue and expand existing partnerships with several key charities and non-profits in 2020. These initiatives are part of an extensive corporate social responsibility program spearheaded by French Transit CEO Martin Floreani.

"It is no longer enough to be 'clean' or 'cruelty-free' in a passive manner," says Floreani. "We also need to be proactive in our stewardship of the planet and its resources. We need to put our time, money and full commitment behind our mission which we define as Clean & Caring." Floreani will be a key panelist during a Natural Products Expo West education seminar in March dedicated to helping other companies define and grow their own corporate social responsibility programs.

"Brands need to embrace cruelty-free research processes, but our company goes beyond by supporting organizations like The Gentle Barn that foster vegan and cruelty-free lifestyles." The Gentle Barn is a non-profit organization dedicated to ending animal cruelty and animal testing that is unfortunately still a reality in the beauty and personal care category. It provides sanctuary for abused and neglected animals and allows inner-city and at-risk children to interact with them, promoting respect and responsibility. MyChelle and CRYSTAL brands supported the Gentle Barn's "Gentle 12 program" for the month of August, and served as title sponsors for the charity's 20th Anniversary Gala in September and have confirmed their renewed commitment for 2020.

MyChelle Dermaceuticals will also continue and expand its support of The Coral Restoration Foundation, the world's largest nonprofit marine-conservation organization dedicatedto restoring our planet's coral reefs to a healthy state. MyChelle was one of the first cosmetic manufacturers to reject marine-toxic ingredients, including oxybenzone, octinoxate, butylparaben, retinyl palmitate and 4-methylbenzylidene camphor. "MyChelle is dedicated not only to creating reef-friendly sun care but also helping organizations such as the Coral Restoration Foundation to preserve and grow reefs," said Floreani. Last July, the company donated 1% of all net proceeds from online sales to the Foundation. This year MyChelle will continue its support of the Coral Restoration Foundation but is also working to be the first brand in its category to incorporate ocean recycled plastic into its packaging.

French Transit is also a recurring sponsor of Breast Cancer Prevention Partners (BCPP), an organization that raises awareness of toxic chemicals used in many personal care products. In 2019, during Breast Cancer Awareness Month, French Transit donated 1% of net sales from their websites to the organization, a commitment that will be repeated in 2020.

"We look forward to building upon our work with these amazing and truly impactful organizations in 2020," said Floreani. "And we are excited and proud to be a leader in a growing community of personal care companies who actively go beyond their claims to foster positive change and real results."

http://www.mychelle.com (PRNewsFoto/MyChelle Dermaceuticals)" alt="Founded in 2000, the Colorado-based skin care company is credited as the first to successfully develop and market natural skin care products using a combination of anti-aging peptides, plant stem cells, and clinically proven dermatological ingredients. Learn more at http://www.mychelle.com (PRNewsFoto/MyChelle Dermaceuticals)">

View original content to download multimedia:http://www.prnewswire.com/news-releases/french-transit-brands-to-expand-their-corporate-social-responsibility-programs-in-2020-300974956.html

SOURCE French Transit

Read more here:
French Transit Brands to Expand their Corporate Social Responsibility Programs in 2020 - Benzinga

Skin Stem Cells Comments Off on French Transit Brands to Expand their Corporate Social Responsibility Programs in 2020 – Benzinga | December 16th, 2019

According to a recent report published by Persistence Market Research, the Stem Cell-Derived Cells Market is expected to witness a CAGR growth of ~XX% over the forecast period 2019 2029 and reach a value of ~US$ by the end of 2029. Furthermore, the micro and macro-economic elements that are forecasted to influence the trajectory of the Stem Cell-Derived Cells Market are thoroughly analyzed in the presented market study.

The report throws light on the various raw material suppliers, vendors, manufacturers, and market players in the value chain of the Stem Cell-Derived Cells Market. Further, the economic and political scenarios of various regions and its impact on the Stem Cell-Derived Cells Market are thoroughly discussed in the report.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) athttps://www.persistencemarketresearch.co/samples/28780

The report studies and provides key analysis in the shape of Stem Cell-Derived Cells Market dynamics such as the drivers, restraints, trends, opportunities, forecast factors and value chain that impact the Stem Cell-Derived Cells Market.

Critical insights enclosed in the report:

The competitive outlook chapter throws light on the business prospects of prominent players operating in the Stem Cell-Derived Cells Market. The product pricing strategies, preferred marketing channels, product portfolio of prominent players, and market presence of each company is included in the report.

The report caters to the following queries pertaining to the Stem Cell-Derived Cells Market:

Get Access To TOC Covering 200+ Topics athttps://www.persistencemarketresearch.co/toc/28780

The presented market study sheds light on the market scenario in different regional markets. In addition, the impact of the regulatory and governmental policies on the prospects of the Stem Cell-Derived Cells Market in each region is analyzed in the report. The report offers comprehensive data on the growth parameters and market dynamics for each of these regions

key players in stem cell-derived cells market are focused on generating high-end quality cardiomyocytes as well as hepatocytes that enables end use facilities to easily obtain ready-made iPSC-derived cells. As the stem cell-derived cells market registers a robust growth due to rapid adoption in stem cellderived cells therapy products, there is a relative need for regulatory guidelines that need to be maintained to assist designing of scientifically comprehensive preclinical studies. The stem cell-derived cells obtained from human induced pluripotent stem cells (iPS) are initially dissociated into a single-cell suspension and later frozen in vials. The commercially available stem cell-derived cell kits contain a vial of stem cell-derived cells, a bottle of thawing base and culture base.

The increasing approval for new stem cell-derived cells by the FDA across the globe is projected to propel stem cell-derived cells market revenue growth over the forecast years. With low entry barriers, a rise in number of companies has been registered that specializes in offering high end quality human tissue for research purpose to obtain human induced pluripotent stem cells (iPS) derived cells. The increase in product commercialization activities for stem cell-derived cells by leading manufacturers such as Takara Bio Inc. With the increasing rise in development of stem cell based therapies, the number of stem cell-derived cells under development or due for FDA approval is anticipated to increase, thereby estimating to be the most prominent factor driving the growth of stem cell-derived cells market. However, high costs associated with the development of stem cell-derived cells using complete culture systems is restraining the revenue growth in stem cell-derived cells market.

The global Stem cell-derived cells market is segmented on basis of product type, material type, application type, end user and geographic region:

Segmentation by Product Type

Segmentation by End User

The stem cell-derived cells market is categorized based on product type and end user. Based on product type, the stem cell-derived cells are classified into two major types stem cell-derived cell kits and accessories. Among these stem cell-derived cell kits, stem cell-derived hepatocytes kits are the most preferred stem cell-derived cells product type. On the basis of product type, stem cell-derived cardiomyocytes kits segment is projected to expand its growth at a significant CAGR over the forecast years on the account of more demand from the end use segments. However, the stem cell-derived definitive endoderm cell kits segment is projected to remain the second most lucrative revenue share segment in stem cell-derived cells market. Biotechnology and pharmaceutical companies followed by research and academic institutions is expected to register substantial revenue growth rate during the forecast period.

North America and Europe cumulatively are projected to remain most lucrative regions and register significant market revenue share in global stem cell-derived cells market due to the increased patient pool in the regions with increasing adoption for stem cell based therapies. The launch of new stem cell-derived cells kits and accessories on FDA approval for the U.S. market allows North America to capture significant revenue share in stem cell-derived cells market. Asian countries due to strong funding in research and development are entirely focused on production of stem cell-derived cells thereby aiding South Asian and East Asian countries to grow at a robust CAGR over the forecast period.

Some of the major key manufacturers involved in global stem cell-derived cells market are Takara Bio Inc., Viacyte, Inc. and others.

The report covers exhaustive analysis on:

Regional analysis includes

Report Highlights:

In order to get a strategic overview of the market,Access Research Methodology Prepared By Experts athttps://www.persistencemarketresearch.co/methodology/28780

Reasons why you should choose PMR

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact us:

Persistence Market Research305 Broadway, 7th FloorNew York City, NY 10007United StatesPh.no. +1-646-568-7751

This post was originally published on Downey Magazine

Read more:
Stem Cell-Derived Cells Market To Boost Demand And Forecast In Upcoming Year 2019 2029 - Downey Magazine

IPS Cell Therapy Comments Off on Stem Cell-Derived Cells Market To Boost Demand And Forecast In Upcoming Year 2019 2029 – Downey Magazine | December 16th, 2019

Sometimes when hes asleep, Nick Hernandez has this dream.

The 54-year-old Homer Glen man is playing baseball for a professional team. He hits a ball down the line. He smells the grass. Everything is normal, vividly normal.

And then

Hernandez wakes up in a body that had a C-6 spinal injury 37 years ago.

Before the accident, Hernandez played basketball and baseball for the former Joliet Catholic High School (now Joliet Catholic Academy). He was a college prospect for both sports and was to serve as team captain for both sports his senior year.

Hernandez also was a scholar, ranking 30th out of 205 students. His grade-point average was 4.03

I loved Joliet Catholic, Hernandez said, even though I felt like a fish out of water freshman year because all my friends went to Lockport.

Hernandez has remained close to his Catholic High family through the years. And like a good family, this close group of his friends is raising $75,000 to buy Hernandez a new special needs van, which will keep him mobile and independent.

His current van is 19 years old, and Hernandezs mechanic said it soon will be unsafe to drive, Hernandez said.

Hernandez appreciates their friendship and expressed it more than once.

Im the luckiest guy on the face of the earth, he said, despite the injury.

The injury that changed his life happened Aug. 4, 1982.

It was 9:30 p.m. and Hernandez was driving home from a friends house. He was on 143rd Street, less than a mile from home, when two horses jumped out. He remembers the impact, the horses coming down on top of my vehicle before slipping into unconsciousness.

I woke up a few minutes later in the vehicle, Hernandez said. My rearview mirror was bent and facing me, and I had blood streaming down my face. I could not move, and I was in a great deal of pain, neck pain Id never felt before. I kind of knew immediately. I just knew I had a spinal cord injury.

Oddly enough, he said, a friend of the family recently had a neck injury while swimming, an incident Hernandez had only vaguely noted at the time, but something he recalled in that moment, with his vehicle on the opposite side of the road and the nice cut in the top of my head, which would leave a permanent scar.

But a scar was not Hernandezs concern at the time.

My job was just to fight, to try to stay alive, quite honestly, Hernandez said.

His parents, Nick Sr. and Madeleine, soon arrived on the scene; a priest gave last rites on the spot. Hernandez recalled thinking, Well, this is how it ends.

Hernandez said he was taken to Silver Cross to be stabilized and was transferred to Northwestern Memorial Hospital that night, his home until December. He spent three days in the intensive care unit, where he was given morphine to help him sleep, Hernandez said.

He wore a brace that was drilled into his temples to stabilize his spine You feel like Frankenstein, Hernandez said, and he was periodically rotated every two hours, as if he was on a rotisserie, he said.

It was a do-or-die situation, Hernandez said. I guess something inside me said, Youre still alive. You have to. Too many people just cared about me, I guess this was long before Christopher Reeve. I was just a kid who fought to stay alive.

Hernandezs weight dropped from 180 to 130 pounds as his muscles atrophied, he said. He learned to breathe through his diaphragm.

The experience forced him to grow up fast, he said, which he did, with the help of family, friends, teammates and coaches (Mike Gillespie coached Hernandez for basketball ,and Jack Schimanski coached Hernandez for baseball) who visited him.

I never wrapped my arms around how it could be so emotional for someone else, Hernandez said. Its the ripple effect I didnt understand at the time.

When physical therapy was completed, Hernandez returned to Catholic High to complete his senior year and graduated with honors. While there, he attended school events prom, as well as baseball and basketball games.

He eventually relearned to drive, using hand controls in a modified van. It was frightening at first, until Hernandez moved past that fear.

I wanted to be on the road again, Hernandez said. Thats the one thing about driving; it gives you that freedom.

He worked for medical supply companies until he wound up with pressure ulcers in 2010 that led to a bone infection and a flap surgery to correct it.

It was not a good time in my life, Hernandez said.

But it gave him time to reevaluate his life. He moved back to his parents house, where he now lives in a basement apartment. He now focuses his energy on taking better care of himself and spending time with loved ones, including going to movies with his girlfriend.

He still deals with nerve pain, although some days are better than others, he said.

Hernandez exercises at home with the use of a standing table (which puts pressure on his bones and reminds people just how tall he is at 6-foot-4) and swims using a modified butterfly stroke all summer in the family pool.

I just drag my legs behind me, Hernandez said. I may do 30 to 40 laps in the pool. Its really, really helpful for one with a spinal cord injury, or anybody really, when rehabbing. The water is a good way to exercise without putting too much pressure on the body.

Watching athletes, especially his nieces and nephews who play sports, from the sidelines has given Hernandez an appreciation of the capabilities of the human body when all parts work in unison.

And he thinks, I used to do that

But Hernandez has learned to deal with it, he said.

Because the other options arent pretty, Hernandez said. So if not for my family and friends, and obviously my belief in God you have doubts here and there, but I still have my faith I can hang in there if you can laugh with this injury, you can make it another day. As long as the good Lord wants you around, youll still be there. Im not preaching to anybody, but this is how I choose to live.

Hernandez still clings to his dream, his dream of walking one day.

Hes extremely excited about a Nov. 27 report from Mayo Clinic about how STEM cells from a patients fat can improve sensory motor function in people with spinal cord injuries.

If I just keep myself in shape, maybe, if Im here in another five years, maybe I can still walk, Hernandez said. It kind of keeps you motivated.

HOW TO HELP

Visit gofundme.com/f/new-wheels-for-nick-in-2020 or make checks payable to Nick Hernandez and mail to Al Petro, 4712 Galway Road, Joliet, IL 60431.

Visit link:
'I was just a kid trying to stay alive' - The Herald-News

Spinal Cord Stem Cells Comments Off on ‘I was just a kid trying to stay alive’ – The Herald-News | December 16th, 2019

Gary L. Dunbar, executive director of the Field Neurosciences Institute, part of Ascension St. Mary's, was recently presented with the Gusi Peace Prize International Award.

Dr. Dunbar recently traveled to Manila, Philippines to accept this honor at the Gusi Peace Prize International 20th Annual Awards Night.

The Gusi Peace Prize award is given by the Gusi Peace Prize Foundation to recognize individuals and organizations who contribute to global peace and progress through a wide variety of fields. Dunbar was one of 18 international recipients selected for the award and chosen because of his global contributions in both the educational and the research domains of neuroscience. Similarly, his contributions in research, especially for developing new strategies for treating damage to the nervous system, including transplantation of genetically altered adult stem cells as a potential therapy for injury to the brain and spinal cord as well as neurological deficits in Huntington's, Parkinson's and Alzheimer's diseases, has earned international recognition and a prominent leadership role in the American Society for Neural Therapy and Repair.

"I felt both honored and humbled to be selected for the Gusi Peace Prize, especially after meeting and hearing, first-hand, what the other 2019 Gusi Laureates have accomplished in the context of helping others, which was humbling to me," shared Dunbar. "The prize is given to those whose efforts have provided significant improvements to the lives of others through education, research, politics, and/or the arts, along with a strong commitment to humanitarian commitments, so I felt deeply honored to be included in this group of people."

Dunbar has been the executive director for the Field Neurosciences Institute since 2008. Martha Ann Joseph, Chair of the institute's board of directors, was thrilled to hear that Dunbar was a recipient of the Gusi Peace Prize International Award.

"(Field Neurosciences Institute) is blessed to have Dr. Dunbar as our executive director for the past 11 years as he has always embraced the mission of the organization, to help others in terms of preventing brain injury and searching for cures for neurological problems emanating from trauma and disease to the nervous system," Joseph said.

"Dr. Dunbar embodies the very premise of the Gusi award in attaining peace and dignity for fellow humans by his tireless devotion to finding new ways to treat a variety of neurological disorders and for his dedicated efforts in educating the next generation of neuroscientists, physicians, and health-care providers at the highest level," added E. Malcolm Field, Field Neurosciences Institute director.

Presently, Dunbar holds the John G. Kulhavi Professorship in Neuroscience, as well as the E. Malcolm Field Endowed Chair in Neuroscience at CMU.

The Gusi Peace Prize was founded by the Honorable Ambassador Barry Gusi, to honor and continue the work of his late father, Captain Gemeniano Javier Gusi, who fought against Japanese oppression during World War II and later championed human rights in the Philippines. For 20 years, the Gusi Peace Prize Award has been awarded to prominent individuals from all over the world who have made significant contributions to the betterment of humankind.

Here is the original post:
International Peace Prize awarded to Ascension St. Mary's executive director - Midland Daily News

Spinal Cord Stem Cells Comments Off on International Peace Prize awarded to Ascension St. Mary’s executive director – Midland Daily News | December 16th, 2019

Cell processing involves a series of activities ranging from cells collection from donor, cell extraction till the storage, and cells distribution to receiver for cell therapy. Cell processing includes various processes of cell collection, cell isolation, cell analysis, cell expansion, washing and concentration, preservation, and distribution.

Cell therapy refers to administering of living whole cells in a patient for treating a disease. Cells origin can be from the same individual, known as autologous source or from another individual, known as allogeneic source. For cell therapy, different types of cells can be used, including hematopoietic stem cells, skeletal muscle cells, embryonic stem cells, neural cells, and mesenchymal cells. Cell therapy is used for the treatment of autoimmune diseases, cancers, infectious and urinary diseases, repairmen of spinal cord injuries, rebuilding damaged cartilage in joints, improvement of a weakened immune system, and aiding patients with neurological disorders.

Key Drivers of Global Cell Processing Technologies Market

Increase in demand for cell therapy, as it is the only curative treatment for several diseases, such as autoimmune disease, cancer, and neural disease. This factor is responsible for growth of the global cell processing technologies market.

There is a rise in prevalence of various diseases, such as cancer, immune diseases, neurological disorders, cardiovascular disease, etc. According to the National Cancer Institute, in 2016, there were an estimated 15.5 million cancer survivors in the U.S. The number of cancer survivors is anticipated to increase to 20.3 million by 2026.

Request a PDF Sample on Cell Processing Technologies Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=73602

Personalized medicines or precision medicines with advanced treatments such as gene therapy and cell therapy are witnessing a surge in their adoption, as most of the key biotechnology and pharmaceutical players are heavily investing in these technologies

Government investments in cell-based researches, rise in the number of GMP-certified production facilities, and increase in clinical trials of various diseases are key factors propelling the growth of the global cell processing technologies market

Key Restraints of Global Cell Processing Technologies Market

Cell processing is a complex procedure with high probabilities of failure. Thus, its complexity and accuracy demand technologically advanced and high-tech infrastructure, along with a skilled operating staff. These incur high infrastructural and operating costs, which limit its adoption on a large scale.

High operating cost also leads to high cell therapy cost to patients. However, at present, the cell therapy is approved for a limited number of conditions, which further limits the usage of cell processing technologies and services

Equipment Segment of Cell Processing Technologies Market to Witness Strong Growth

Complexity in cell processing steps and accuracy required for procedure has led to the development of advanced automated cell processing systems. Key players have been heavily investing in the development of advanced cell processing systems. Advancements in software for managing these systems are projected to expand the application areas for cell processing units.

In May 2018, GE Healthcare introduced the Sefia S-2000 cell processing system, which is advanced than its predecessor Sefia S-1000 cell processing system. This advanced system was developed with focus on chimeric antigen receptor (CAR) T-cell therapy.

Investments in CAR-T and other cell and gene therapy products are projected to drive the adoption of cell processing equipment. As the installed base for cell processing systems is projected to surge, the demand for consumables is likely to grow during the forecast period.

Pre Book this Report

https://www.transparencymarketresearch.com/checkout.php?rep_id=73602&ltype=S

Oncology is projected to be the most promising application area of cell processing technology, considering high investments and ongoing research in cell therapies for cancer treatment and high investment made by key biotechnology and pharmaceutical companies in this area.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving method-ologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of re-search is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY 12207United StatesTel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: http://www.transparencymarketresearch.comBlog: https://theglobalhealthnews.com/

Read the original here:
Cell Processing Technologies Market Segments, Leading Player, Application and Forecast Analysis - Techi Labs

Spinal Cord Stem Cells Comments Off on Cell Processing Technologies Market Segments, Leading Player, Application and Forecast Analysis – Techi Labs | December 16th, 2019

Article courtesy of : Dr. Brent Wells, D.C.

While it is very important to be sure the whole body is healthy and maintains that good health, its also important to understand key factors regarding why the health of the spine in particular; is important. Not only is a healthy spine important for the back area, obviously, but its also beneficial in terms of the body as a whole.

Because the spine and back must be kept healthy, its understanding how it affects the rest of the body that helps one to strive to reach that level of health. Some patients dont always understand the way a healthy spine assists in maintaining a healthy immune system within. However, as an Anchorage chiropractor, I am constantly showing my patients the importance of this health aspect.

To maintain a healthy and active life requires one to have a healthy spine. Maintaining a consistent good posture is one key factor that assists the body in terms of that.

Its important to keep in mind that the spine is responsible for supporting the body along with providing structure to the body. Without support or structure, the body will eventually fail and wont be able to perform daily functions.

The spinal cord alone is responsible for certain reflexes where the body is responding quickly to outside stimulants (ex. Your hand touching a hot stove and quickly and immediately removing the hand from the heat and pain). Therefore, anytime the spine is misaligned, the body is at risk of losing those necessary functions.

Anytime the spine is imbalanced, some other aspect of the body runs the risk of being compromised. Typically, the immune system is hindered because of an imbalance in the spine. A compromised spine means that the Central Nervous System is compromised, and when the CNS is compromised, the necessary responses regarding the immune system of the body are challenged.

The spinal cord houses very important nerves that directly communicate with the brain, being sure the rest of the body understands what to do and how to move.

Balance can also be affected when the spine is in a vulnerable position. Every movement that the body makes is coming from the connection of the spinal cord and the brain, minus those reflexes solely stemming from the spinal cord.

First, let's define posture. Posture is defined as the way you hold your body not only when standing but lying down and sitting also. In every position, it's very important to learn how to practice good posture.

When practicing good posture, you place less of a strain upon your back due to focusing on maintaining the position that keeps everything within its proper alignment.

A neutral spinal position is the only position that is beneficial to the health of the spine. Any other position brings more strain, causes further back issues and can create future issues with the curvature of the spine.

Good posture is important because it leads to healthy spines and long-term success overall in terms of the body.

There are signs you can be mindful of that will help you in knowing whether an adjustment is what you need. When the spine is out of alignment there are cases where once adjustment is all a patient may need, and in average situations, a few visits usually do the trick.

A chiropractor can help you on your journey to a healthy spine whether its a massage you desire, spinal manipulation, spinal mobilization, or physical therapy; the main goal and the desire that we have for you is that you leave pain free and enjoy living with a healthy back.

In terms of the head, neck, shoulders, and hips, if you are unable to move your head and neck without a struggle and pain; it may be time for an adjustment.

The hips along with the neck are central points that can generally aid in helping you better know whats going on with your spine. A loss of mobility and an increase of stiffness and unaddressed pains and aches can symbolize a need for an adjustment.

Because the CNS is made up of the spinal cord and the brain, when the spine is out of its proper position, the functioning it provides for the rest of the body is altered.

The immune system responses lack when the spine is being challenged, seeing that the nerves that are being housed are unable to receive the proper commands from the brain to then go throughout the body. (Ex. The body requires certain signaling of blood cells to respond and fight against the common cold, but because those nerves are compromised, the body won't receive the warnings and signals, therefore disabling the immune system to fully operate and function as highly as it should).

The level of tiredness we experience from day to day can stem from the pain our bodies sometimes deal with. It takes work for the body to fight off the pain it experiences especially pain that affects the whole body.

In some cases, the reason behind fatigue is indeed the need for an adjustment to the spine. If youre feeling rather fatigued and youre also experiencing specifically pain in the neck, back or shoulder area; it could be beneficial for you to visit your local chiropractor and talk business.

Remember that visiting your local chiropractor can and will assist you in better living a life free of abnormal curvatures within the spine. Further enabling your health to improve, and your body will experience more flexibility, coordination, better responses, and your balance will be sure to improve.

Originally posted here:
The Importance Of Good Posture And Spinal Health - Anti Aging News

Spinal Cord Stem Cells Comments Off on The Importance Of Good Posture And Spinal Health – Anti Aging News | December 16th, 2019

An exhaustive study report on the Stem Cell-Derived Cells Market published by Persistence Market Research offers an in-depth understanding of the critical aspects that are expected to propel the growth of the Stem Cell-Derived Cells Market in the foreseeable future. Furthermore, by analyzing the data enclosed in the report, leading investors, stakeholders and upcoming market players can devise strategic methodologies to gather momentum and enhance their global footprint in the current Stem Cell-Derived Cells Market landscape.

As per the critical nuances of the study, the Stem Cell-Derived Cells market is poised to grow at a CAGR of ~XX% and attain a value of ~US$XX by the end of 2029. Prevailing and future prospects of the Stem Cell-Derived Cells Market gives readers a sinuous understanding and detailed market intelligence of the Stem Cell-Derived Cells Market landscape.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) athttps://www.persistencemarketresearch.co/samples/28780

Important Aspects Related to the Stem Cell-Derived Cells Market Included in the Report

The report answers the following questions related to the Stem Cell-Derived Cells Market:

Get Access To TOC Covering 200+ Topics athttps://www.persistencemarketresearch.co/toc/28780

key players in stem cell-derived cells market are focused on generating high-end quality cardiomyocytes as well as hepatocytes that enables end use facilities to easily obtain ready-made iPSC-derived cells. As the stem cell-derived cells market registers a robust growth due to rapid adoption in stem cellderived cells therapy products, there is a relative need for regulatory guidelines that need to be maintained to assist designing of scientifically comprehensive preclinical studies. The stem cell-derived cells obtained from human induced pluripotent stem cells (iPS) are initially dissociated into a single-cell suspension and later frozen in vials. The commercially available stem cell-derived cell kits contain a vial of stem cell-derived cells, a bottle of thawing base and culture base.

The increasing approval for new stem cell-derived cells by the FDA across the globe is projected to propel stem cell-derived cells market revenue growth over the forecast years. With low entry barriers, a rise in number of companies has been registered that specializes in offering high end quality human tissue for research purpose to obtain human induced pluripotent stem cells (iPS) derived cells. The increase in product commercialization activities for stem cell-derived cells by leading manufacturers such as Takara Bio Inc. With the increasing rise in development of stem cell based therapies, the number of stem cell-derived cells under development or due for FDA approval is anticipated to increase, thereby estimating to be the most prominent factor driving the growth of stem cell-derived cells market. However, high costs associated with the development of stem cell-derived cells using complete culture systems is restraining the revenue growth in stem cell-derived cells market.

The global Stem cell-derived cells market is segmented on basis of product type, material type, application type, end user and geographic region:

Segmentation by Product Type

Segmentation by End User

The stem cell-derived cells market is categorized based on product type and end user. Based on product type, the stem cell-derived cells are classified into two major types stem cell-derived cell kits and accessories. Among these stem cell-derived cell kits, stem cell-derived hepatocytes kits are the most preferred stem cell-derived cells product type. On the basis of product type, stem cell-derived cardiomyocytes kits segment is projected to expand its growth at a significant CAGR over the forecast years on the account of more demand from the end use segments. However, the stem cell-derived definitive endoderm cell kits segment is projected to remain the second most lucrative revenue share segment in stem cell-derived cells market. Biotechnology and pharmaceutical companies followed by research and academic institutions is expected to register substantial revenue growth rate during the forecast period.

North America and Europe cumulatively are projected to remain most lucrative regions and register significant market revenue share in global stem cell-derived cells market due to the increased patient pool in the regions with increasing adoption for stem cell based therapies. The launch of new stem cell-derived cells kits and accessories on FDA approval for the U.S. market allows North America to capture significant revenue share in stem cell-derived cells market. Asian countries due to strong funding in research and development are entirely focused on production of stem cell-derived cells thereby aiding South Asian and East Asian countries to grow at a robust CAGR over the forecast period.

Some of the major key manufacturers involved in global stem cell-derived cells market are Takara Bio Inc., Viacyte, Inc. and others.

The report covers exhaustive analysis on:

Regional analysis includes

Report Highlights:

In order to get a strategic overview of the market,Access Research Methodology Prepared By Experts athttps://www.persistencemarketresearch.co/methodology/28780

Why are PMRs Analytical Insights the Best?

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact us:

Persistence Market Research305 Broadway, 7th FloorNew York City, NY 10007United StatesPh.no. +1-646-568-7751

This post was originally published on Downey Magazine

Read the rest here:
Stem Cell-Derived Cells Market Expected to Expand at a Steady CAGR through 2019 2029 - Downey Magazine

IPS Cell Therapy Comments Off on Stem Cell-Derived Cells Market Expected to Expand at a Steady CAGR through 2019 2029 – Downey Magazine | December 15th, 2019

ALAMEDA, Calif.--(Business Wire)--AgeX Therapeutics, Inc. (NYSE American: AGE) and Lineage Cell Therapeutics, Inc. (NYSE American and TASE LCTX), announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,501,723, entitled Methods of Reprogramming Animal Somatic Cells covering what is commonly designated induced Pluripotent Stem (iPS) cells. The issued claims include methods to manufacture pluripotent cells capable of becoming any cell in the body. The patent has an early priority date, having been filed before the first scientific publication of Shinya Yamanaka, for which he won the Nobel Prize for Physiology or Medicine in 2012.

This patent broadly describes multiple techniques for reprogramming cells of the body back to the all-powerful stem cell state, said Dr. Michael D. West, CEO of AgeX and first inventor on the patent. Perhaps more significantly, it includes certain factors that address some of the difficulties currently encountered with iPS cells. It also reflects the foundational work our scientists have undertaken to apply reprogramming technology to age-reversal, specifically, induced Tissue Regeneration (iTR) which is currently a focus of AgeX product development. A video describing the significance of the patent in AgeXs product development is available on the AgeX website.

The issuance of this patent highlights Lineages dominant position in the field of cell therapy, stated Brian M. Culley, CEO of Lineage. Our efforts to develop new treatments rely on well-characterized and NIH-approved human cell lines. These lines are not genetically manipulated, which avoids the safety concerns associated with genetic aberrations arising from the creation of iPS cells. We believe the Lineage cell lines provide the safest option for our current clinical-stage programs, particularly in immune-privileged anatomical sites such as the eye (OpRegen for the treatment of dry AMD) and spinal cord (OPC1, for the treatment of spinal cord injury). However, the vast intellectual property estate which underlies our cell therapy platform has never been limited to these particular cell lines. As one example, this newly-issued patent provides us with proprietary methods for producing induced pluripotent stem cells, or, as it was practiced by us prior to Yamanaka, Analytical Reprogramming Technology (ART). In certain settings, an ART/iPS approach might offer important advantages, such as for an autologous treatment or when the selection of preferential attributes from a series of iPS lines is desirable. Questions as to which stem cell technology is preferred ultimately will be answered by clinical safety and efficacy and likely will be indication-specific, so we believe it is in the best interest of our shareholders to generate patented technology which enables us to pursue programs in either or both formats which we believe will ensure the highest probability of success.

Induced Pluripotent Stem Cells (iPS) are typically derived from adult skin or blood cells which have been reprogrammed or induced to retrace their developmental age and regain the potential to form all of the young cell and tissue types of the body. In 2010 inventors of the -723 patent issued today demonstrated that this reversal of developmental aging even extended to the telomere clock of cell aging. This reprogramming technology provides an alternate source of starting material for the manufacture of potentially any type of human cell needed for therapeutic purposes. Because iPSCs can be derived directly from adult tissues, they can be used to generate pluripotent cells from patients with known genetic abnormalities for drug discovery or as an alternative source of cell types for regenerative therapies.

U.S. Patent No. 10,501,723, entitled Methods of Reprogramming Animal Somatic Cells was assigned to Advanced Cell Technology of Marlborough, Massachusetts (now Astellas Institute for Regenerative Medicine) and licensed to Lineage and sublicensed to AgeX Therapeutics for defined fields of use. Inventors of the patent include Michael D. West, CEO of AgeX and previous CEO of Advanced Cell Technology, Karen B. Chapman, Ph.D., and Roy Geoffrey Sargent, Ph.D.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly-defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies in the body. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan and is seeking opportunities to establish licensing and collaboration agreements around its broad IP estate and proprietary technology platforms.

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineages programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineages clinical assets include (i) OpRegen, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer. Lineage is also evaluating potential partnership opportunities for Renevia, a facial aesthetics product that was recently granted a Conformit Europenne (CE) Mark. For more information, please visit http://www.lineagecell.com or follow the Company on Twitter @LineageCell.

Forward-Looking Statements

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the Risk Factors section of AgeXs Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191210005435/en/

Media Contact for AgeX:Bill Douglass Gotham Communications, LLCbill@gothamcomm.com (646) 504-0890

Read more:
AgeX Therapeutics and Lineage Cell Therapeutics Announce Issuance of US Patent for Method of Generating Induced Pluripotent Stem Cells - Press Release...

IPS Cell Therapy Comments Off on AgeX Therapeutics and Lineage Cell Therapeutics Announce Issuance of US Patent for Method of Generating Induced Pluripotent Stem Cells – Press Release… | December 15th, 2019

VALLEY COTTAGE, N.Y. Stem cells are undifferentiated biological cells, and having remarkable potential to divide into any kind of other cells. When a stem cell divides, each new cell will be a new stem cell or it will be like another cell which is having specific function such as a muscle cell, a red blood cell, brain cell and some other cells.

There are two types of stem cells

Stem cells harvested from umbilical cord blood just after birth. And this cells can be stored in specific conditions. Stem cells also can be harvest from bone marrow, adipose tissue.

Embryonic cells can differentiate into ectoderm, endoderm and mesoderm in developing stage. Stem cells used in the therapies and surgeries for regeneration of organisms or cells, tissues.

Stem cells are used for the treatment of Gastro intestine diseases, Metabolic diseases, Immune system diseases, Central Nervous System diseases, Cardiovascular diseases, Wounds and injuries, Eye diseases, Musculoskeletal disorders.

Download the sample copy of Report with table of contents and Figures @: https://www.futuremarketinsights.com/reports/sample/rep-gb-1087

Harvesting of Adult cell is somewhat difficult compare to embryonic cells. Because Adult cells available in the own body and it is somewhat difficult to harvest.

Stem Cell TherapiesMarket: Drivers and Restraints

Technology advancements in healthcare now curing life threatening diseases and giving promising results. Stem Cell Therapies having so many advantages like regenerating the other cells and body organisms. This is the main driver for this market. These therapies are useful in many life threatening treatments. Increasing the prevalence rate of diseases are driven the Stem Cell Therapies market, it is also driven by increasing technology advancements in healthcare. Technological advancements in healthcare now saving the population from life threatening complications.

Increasing funding from government, private organizations and increasing the Companies focus onStem cell therapiesare also driven this market

However, Collecting the Embryonic Stem cells are easy but Collecting Adult Stem cell or Somatic Stem cells are difficult and also we have to take more precautions for storing the collected stem cells.

Preview Analysis of Stem Cell Therapies Market: Global Industry Analysis and Opportunity Assessment 2015 2025: https://www.futuremarketinsights.com/reports/stem-cell-therapies-market

Stem Cell TherapiesMarket: Segmentation

Stem Cell Therapies are segmented into following types

Based on treatment:

Based on application:

Based on End User:

Stem Cell TherapiesMarket: Overview

With rapid technological advantage in healthcare and its promising results, the use of Stem Cell Therapies will increase and the market is expected to have a double digit growth in the forecast period (2015-2025).

Stem Cell TherapiesMarket: Region- wise Outlook

Depending on geographic regions, the global Stem Cell Therapies market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific excluding Japan, Japan and Middle East & Africa.

The use of Stem Cell Therapies is high in North America because it is highly developed region, having good technological advancements in healthcare setup and people are having good awareness about health care. In Asia pacific region china and India also having rapid growth in health care set up. Europe also having good growth in this market.

Buy this report @https://www.futuremarketinsights.com/checkout/1087

Stem Cell TherapiesMarket: Key Players

Some of the key players in this market are

Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you:https://www.futuremarketinsights.com/askus/rep-gb-1087

More from Healthcare, Pharmaceuticals and Medical devices:

About Us

Future MarketInsights (FMI) is a leading market intelligence and consulting firm. We deliversyndicated research reports, custom research reports and consulting serviceswhich are personalized in nature. FMI delivers a complete packaged solution,which combines current market intelligence, statistical anecdotes, technologyinputs, valuable growth insights and an aerial view of the competitiveframework and future market trends.

Contact UsMr.Abhishek BudholiyaFuture Market Insights616 Corporate Way, Suite 2-9018,Valley Cottage, NY10989,United StatesT:+1-347-918-3531F: +1-845-579-5705T(UK): + 44-(0)-20-7692-8790Sales:sales@futuremarketinsights.comPress Office:Press@futuremarketinsights.comBlog:MarketResearch BlogWebsite:https://www.futuremarketinsights.com/

See original here:
Stem Cell Therapies Market research Likely to Emerge over a Period of 2015-2025 - PharmiWeb.com

Bone Marrow Stem Cells Comments Off on Stem Cell Therapies Market research Likely to Emerge over a Period of 2015-2025 – PharmiWeb.com | December 15th, 2019

GREEN BAY, Wi. (WBAY) - More than 10,000 people couldn't find a match for a bone marrow transplant last year. The family of one Wisconsin teenager in desperate need of a match decided to host their own donor drive during Sunday's Packers game.

Nick Parins, who lives in Land O Lakes, Wisconsin, has T-Cell Lymphoma and needs a bone marrow transplant, but currently there is no match for him.

Its very frustrating for us, his family and friends, that theres so many people out there and so many people in the bank right now but theres just not the match for him, said Erick St. Aubin, Nicks cousin.

On the same day Nick turned 18, Eric St. Aubin and other family and friends gathered just outside Lambeau Field to host a bone marrow donor drive in his honor.

Right after kickoff today we facetimed with him to sing him happy birthday and it was pretty emotional, said St. Aubin.

The family partnered with Be The Match to set up the registration booth. People interested in putting themselves on the global donor registry only needed to provide some basic information and take a cheek swab test.

Its not saying youre signing up today and youre going to donate tomorrow. Thats really far from the truth, said Be The Match Community Engagement Specialist. The reality is its pretty rare to become a match and if you are its a very special thing.

Klingberg says there arent enough people on the registry to help all the patients who need bone marrow transplants.

This is their last hope. So its really frustrating when you hear people Oh, its really painful or It requires a lot of time or whatever, said Klingberg.

Klingberg says if you are a match, the donation process isnt actually all that painful, and it saves a life.

When somebody comes through and honors that commitment to donate some stem cells, thats all it took, and then this person is coming out of the hospital and going to overcome their disease, said Klingberg. Its amazing and it gives me goosebumps every time.

St. Aubin hopes the event will spread awareness and possibly lead to a life saved.

You could be a match [with someone] across the world, or you might be a match for Nick.

To register as a bone marrow donor, or for more information CLICK HERE.

Follow this link:
Bone marrow donor drive held in Green Bay for teen who needs a match - WBAY

Bone Marrow Stem Cells Comments Off on Bone marrow donor drive held in Green Bay for teen who needs a match – WBAY | December 15th, 2019

However, we may finally have a solution to the First Worlds most enduring problem, baldness, as according to new research, it is certainly possible to create new hair follicles when theyve redeposited themselves to the foot of your shower, through the application of stem-cell technology and 3D printing.

There is a caveat, as the results of the technique are not necessarily long-lasting. When you try to clone hair cells, over time they dedifferentiate and stop producing hair, says Robert Bernstein, a dermatologist in Manhattan who specialises in hair transplantation. For a long time, no one could figure out why. But researchers gradually solved the problem. Over the past few years, they noticed that cells spread out when theyre cultured; the follicular structure essentially melts away. The epiphany was that if you can keep the cells together in their teardrop shape so they continue to signal each other, they continue to grow into hair follicles, Bernstein says.

The next step is to create hair farms, according to an entrepreneur who has started such a thing. Stemson Therapeutics is, per The Atlantic, growing hair from stem cellsnot fetal, but stem cells derived from a persons own skin or bloodand implanting hair follicles rich with dermal papillae into the space around a persons old, shrunken, dormant follicle.

Continue reading here:
Science makes baldness optional (if you can afford it) - The Big Smoke Australia

Skin Stem Cells Comments Off on Science makes baldness optional (if you can afford it) – The Big Smoke Australia | December 15th, 2019

For the first time ever, Israeli scientists in Tel Aviv made a 3D printed artificial heart using a patients own cells," proclaims a Washington Post story headlined Researchers create 3D printed heart on April 17 this year.

In the scientific paper published two days earlier, the Israeli scientists describe how they made a bioink out of heart cells and other materials from a patient, and then bioprinted the tissue in the shape of a tiny heart, which was kept alive in a nutrient solution. Their paper makes it clear that this 3D printed heart could not function like a real heart. But the way the research that was projected in media shows how the idea of 3D printed organs is hyped.

Biotechnology has made significant advances, but its still a long way from creating organs that can be transplanted into people. The vasculaturethe network of blood vessels that feeds the organis a challenge.

Stem cell engineering to grow all the cells of an organ in a personalised way to avoid rejection by the recipients immune system is another challenge. And finally, researchers will have to show that a lab organ will work with all the other organs in a human body.

At the same time, the development of 3D bioprinters in the last few years has raised the prospects of making tissues and organs in a more affordable and consistent way because of the speed and precision of the machines. Advances in related fields like nanotechnology and gene editing are also pushing the needle.

These are exciting times, but for startups rushing into this nascent field with huge potential, its as important to be prudent as brave. One way is to go after low hanging fruit instead of the holy grail.

Shift to clinical use

Something like skin is easier to translate into a clinical setting," says Alok Medikepura Anil, director and co-founder of Bengaluru-based 3D bioprinting startup Next Big Innovation Lab (NBIL), which has made human skin in the lab. The skin has good regenerative properties and most of the function of bioprinted skin is to keep infections away, provide nutrition for skin to regenerate and stop the scarring of wounds. Replicating this is easier than replicating the function of a critical organ such as the heart."

This approach contrasts with that of another Bengaluru-based 3D bioprinting startup Pandorum Technologies, founded in 2011 by two researchers at Indian Institute of Science. Pandorum first tried its hand with liver tissue and more recently announced that it had bio-engineered corneal tissue.

Organ tissue for clinical use will require FDA and other approvals. So thats a very expensive proposition," says angel investor Venkat Raju, who took an interest in Pandorum but eventually made a bet on NBIL whose proprietary Innoskin also has non-clinical use in cosmetics testing.

The regulatory environment is evolving. This year, FDA released an RMAT (regenerative medicine and advanced therapy) policy that includes tissue engineering. The FDA wants to fast-track tissue-engineered products if they have a lot of benefits," says Pooja Venkatesh, NBIL co-founder.

Raju feels that startups like NBIL gaining traction and validation could bridge the current gap between academic research and business.

Theres tonnes of research happening across the globe on bioprinting. But universities are struggling to commercialize their research. The fact that NBIL is getting receptive audiences in academia is because they see an opportunity to push their research out."

The Wake Forest Institute of Regenerative Medicine in the US is one of the leading institutions for research in this field. Researchers there are growing tissues for over 40 different areas of the body. They were the first to transplant a lab-grown organ into a 10-year-old patient.

Made-to-order organs

Dr Anthony Atala, who is now the director of the institute, had taken a piece of the boys bladder and grown a new one in the lab over the course of two months. The lab-grown bladder was then transplanted into the patient.

That boy, Luke Massella, went on to become the captain of his school wrestling team. Pretty much I was able to live a normal life after that," Massella, who is now 28, said in a recent interview on BBC.

Stories like that of Massella stoke excitement over futuristic scenarios where you could get made-to-order organs. But researchers admit that there are many unsolved problems in tissue engineering before complex organs like the heart, kidney and liver can be bioprinted. The crash of well-funded San Diego 3D bioprinting startup Organovo, which hit a brick wall in commercializing liver tissue, reminds us to keep the hype in check.

Sumit Chakraberty is a contributing editor with Mint. Write to him at chakraberty@gmail.com.

Go here to read the rest:
Cutting through the hype to get to bioprinted human tissue - Livemint

Skin Stem Cells Comments Off on Cutting through the hype to get to bioprinted human tissue – Livemint | December 15th, 2019

Transparency Market Research (TMR) has published a new report on the global cell separation technology market for the forecast period of 20192027. According to the report, the global cell separation technology market was valued at ~ US$ 5 Bn in 2018, and is projected to expand at a double-digit CAGR during the forecast period.

Cell separation, also known as cell sorting or cell isolation, is the process of removing cells from biological samples such as tissue or whole blood. Cell separation is a powerful technology that assists biological research. Rising incidences of chronic illnesses across the globe are likely to boost the development of regenerative medicines or tissue engineering, which further boosts the adoption of cell separation technologies by researchers.

Expansion of the global cell separation technology market is attributed to an increase in technological advancements and surge in investments in research & development, such as stem cell research and cancer research. The rising geriatric population is another factor boosting the need for cell separation technologies Moreover, the geriatric population, globally, is more prone to long-term neurological and other chronic illnesses, which, in turn, is driving research to develop treatment for chronic illnesses. Furthermore, increase in the awareness about innovative technologies, such as microfluidics, fluorescent-activated cells sorting, and magnetic activated cells sorting is expected to propel the global cell separation technology market.

Request a PDF Sample on Cell Separation Technology Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1925

North America dominated the global cell separation technology market in 2018, and the trend is anticipated to continue during the forecast period. This is attributed to technological advancements in offering cell separation solutions, presence of key players, and increased initiatives by governments for advancing the cell separation process. However, insufficient funding for the development of cell separation technologies is likely to hamper the global cell separation technology market during the forecast period. Asia Pacific is expected to be a highly lucrative market for cell separation technology during the forecast period, owing to improving healthcare infrastructure along with rising investments in research & development in the region.

Rising Incidences of Chronic Diseases, Worldwide, Boosting the Demand for Cell Therapy

Incidences of chronic diseases such as diabetes, obesity, arthritis, cardiac diseases, and cancer are increasing due to sedentary lifestyles, aging population, and increased alcohol consumption and cigarette smoking. According to the World Health Organization (WHO), by 2020, the mortality rate from chronic diseases is expected to reach 73%, and in developing counties, 70% deaths are estimated to be caused by chronic diseases.

Southeast Asia, Eastern Mediterranean, and Africa are expected to be greatly affected by chronic diseases. Thus, the increasing burden of chronic diseases around the world is fuelling the demand for cellular therapies to treat chronic diseases. This, in turn, is driving focus and investments on research to develop effective treatments. Thus, increase in cellular research activities is boosting the global cell separation technology market.

Increase in Geriatric Population Boosting the Demand for Surgeries

The geriatric population is likely to suffer from chronic diseases such as cancer and neurological disorders more than the younger population. Moreover, the geriatric population is increasing at a rapid pace as compared to that of the younger population. Increase in the geriatric population aged above 65 years is projected to drive the incidences of Alzheimers, dementia, cancer, and immune diseases, which, in turn, is anticipated to boost the need for corrective treatment of these disorders. This is estimated to further drive the demand for clinical trials and research that require cell separation products. These factors are likely to boost the global cell separation technology market.

According to the United Nations, the geriatric population aged above 60 is expected to double by 2050 and triple by 2100, an increase from 962 million in 2017 to 2.1 billion in 2050 and 3.1 billion by 2100.

Request for a Discount on Cell Separation Technology Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1925

Productive Partnerships in Microfluidics Likely to Boost the Cell Separation Technology Market

Technological advancements are prompting companies to innovate in microfluidics cell separation technology. Strategic partnerships and collaborations is an ongoing trend, which is boosting the innovation and development of microfluidics-based products. Governments and stakeholders look upon the potential in single cell separation technology and its analysis, which drives them to invest in the development of microfluidics. Companies are striving to build a platform by utilizing their expertise and experience to further offer enhanced solutions to end users.

See the article here:
Cell Separation Technology Market is Poised to be Worth US$ 13.6 Bn by 2027 - 101Newsindustry

Cardiac Stem Cells Comments Off on Cell Separation Technology Market is Poised to be Worth US$ 13.6 Bn by 2027 – 101Newsindustry | December 15th, 2019

Many of us biologists conduct fieldwork in diverse places, from Alaska to the tropics, from aiming to understand how microbes are responding to climate change in the boreal soils to learning about life history strategies and co-evolutionary arms races of bats, their ectoparasitic flies, and the ectoparasitic fungi living on those flies.

The days before fieldwork tend to be hectic: make a checklist to make sure you have everything you need, think about a plan B (and a plan C, just in case), anticipate drawbacks and plan on how to address them, and the list goes on and on. The day comes. You make it to your field site, you collect the samples you want, obtain the data you need, everything works out just like planned, and you make it back to the lab safe, on time, and without going over your planned budget. This is how it should be, but it never really goes like that.

Fieldwork is one of the most exciting experiences about doing research. It is also, in many cases, high-risk. During fieldwork, many things can go wrong, and most of those things cannot be helped. We cannot control the appearances of massive puddles in the middle of the road, critically damaging our transportation vehicles. We cannot control the thunderstorm that makes our study organisms disappear when we finally arrive at a remote field site after hours of climbing a mud-covered mountain.

Sadly, this is not always the case for threats to our integrity as human beings, and we, as a scientific community, have done far too little to address this problem. People from underrepresented groups in the sciences such as people of color, women, and those who identify as LGBTQIA+ or gender nonconforming often are at higher risk of suffering abuse during fieldwork. This comes in the form of sexual harassment, sexual abuse, discrimination, and intimidation. Scientists who have experienced abuse often fear talking about it because they are traumatized and because they fear retaliation and backlash, especially if the perpetrators of abuse are colleagues or superiors advisers and people at higher career stage.

In Spring 2018, we carried out an anonymous survey to collect testimonies of what scientists, specifically from the LGBTQIA+ community, experience during fieldwork. The idea for such a survey sprouted from concerns that sexual orientation or gender identity may play an unwanted or unwarranted role in peoples professional career. Especially during fieldwork, when Diversity and Inclusion Offices from our university campuses are far away, LGBTQIA+ researchers are exposed to people who may not agree with their sexual orientation or who do not understand why he may want to be addressed as they.

Responses revealed experiences ranging from discrimination to situations that made researchers decide to no longer perform fieldwork outside of safe places. This adds a whole new level to fieldwork stress, namely having to evaluate sites for their tolerance towards LGBTQIA+. In one story from fieldwork, men voiced discomfort because an openly gay man would share a room with them while, simultaneously, women felt uncomfortable due to the possibility of having to share a room with someone from the opposite sex. Another survey respondent described that they were fearful to carry out fieldwork in places that are recognized for their homophobic culture. These experiences leave people feeling isolated and rejected.

We present a few strategies that we can instill in STEM fields to avoid cases like these:

1) INFORM PEOPLE ABOUT LGBTQIA+. Erase any misinformation that may exist. For example, a gay man is not a threat to the sexuality of cisgender males. Institutions can facilitate trainings on diversity and inclusiveness and provide information on the LGBTQIA+ community to eliminate negative stereotypes.

2) HAVE SUFFICIENT FUNDING AVAILABLE FOR FIELDWORK. Although sometimes it's unavoidable to share rooms due to limited budget or space, if there is the possibility to do so, provide individual lodging for people traveling to fieldwork or conferences. Especially for those who ask for it.

3) DEVELOP AN EMERGENCY PROTOCOL. As a lab, department, or institution, develop a protocol that scientists can follow as a response to experiencing a threat to their integrity. Protocols like this should be part of a broader departmental or university-wide mission statement about equity in field work. The bar has been set high by this example of a mission statement written by University of California Irvine professor Kathleen Treseder.

4) AVOID INTOLERANT AREAS. It is important to note that this does not only apply to countries like Niger and Tunisia where discriminatory laws expose LGBTQIA+ individuals to the risk of death penalty. It also applies close to home, in the USA, where there is an ongoing debate about public restrooms and which one transgender people and people who identify as gender-nonconforming should use.

5) IMPLEMENT A ZERO-TOLERANCE POLICY. Inform everyone in your lab, department and institution that there is a zero-tolerance policy regarding abuse. A code of conduct with expected versus unaccepted behavior and practices should always be made available through trainings and in field stations.

Visit link:
Celebrating the Periodic Table of Elements - Massive Science

Cardiac Stem Cells Comments Off on Celebrating the Periodic Table of Elements – Massive Science | December 15th, 2019

SAN DIEGO, Dec. 12, 2019 /PRNewswire/ -- Aspen Neuroscience, Inc. today announced its launch following a $6.5 million seed round led by Domain Associates and Axon Ventures and including Alexandria Venture Investments,Arch Venture Partners,OrbiMedand Section 32 to develop the first autologous cell therapies for Parkinson's disease. Aspen's proprietary approach was developed by the company's co-founders, Jeanne F. Loring, Ph.D., Professor Emeritus and founding director of the Center for Regenerative Medicine at The Scripps Research Institute, and Andres Bratt-Leal, Ph.D., a former post-doctoral researcher in Dr. Loring's lab. The company was initially supported by Summit for Stem Cell, a founding partner and non-profit organization which provides a variety of services for people with Parkinson's disease. Aspen is led by industry veteran Howard J. Federoff, M.D., Ph.D., as Chief Executive Officer.

Parkinson's disease is characterized by the loss of specific brain cells that make the chemical dopamine. Without dopamine, nerve cells cannot communicate with muscles and people are left with debilitating motor problems. Aspen is focusing on human pluripotent stem cells, cultured cells that can become any cell type in the human body. The company's research is specific to induced pluripotent stem cells (iPSCs), which it develops by taking a skin biopsy from a person with Parkinson's disease and turning the tissue into pluripotent stem cells using genetic engineering. Aspen then differentiates the pluripotent stem cells into dopamine-releasing neurons that can be transplanted into that same person (autologous), thereby restoring the types of neurons lost in Parkinson's disease.

As an autologous cell therapy for Parkinson's disease, Aspen's treatment would eliminate the need for immunosuppression because the neurons are transplanted back into the same patient from which they were generated. The use of immunosuppression is necessary with currently available cell therapies for Parkinson's disease and when transplanting cells from one patient to another (allogeneic) to prevent rejection but can pre-dispose the patient to life-threatening complications including infection and add cost to the patient and health system. Aspen is the only company in the world offering an autologous neuron replacement therapy for Parkinson's disease.

Aspen encompasses a powerful executive leadership team including Dr. Federoff who, in addition to his leadership roles at the UC Irvine Health System, was the Executive Vice President for Health Sciences and the Executive Dean of Medicine at Georgetown University. Dr. Federoff also has significant biotech industry experience including co-founding MedGenesis Therapeutix and Brain Neurotherapy Bio, as well as leading the U.S. Parkinson's Disease Gene Therapy Study Group. The company is also proud to announce the addition of several experienced and well-known members to its leadership team including Edward Wirth, M.D., Ph.D., as Chief Medical Officer.

Dr. Wirth currently serves as the Chief Medical Ofcer for Lineage Cell Therapeutics where he oversees clinical development of its two therapeutic programs for spinal cord injuries and lung cancer. He received his M.D. and Ph.D. from the University of Florida in 1994 and remained to conduct postdoctoral research including leading the University of Florida team that performed the rst human embryonic spinal cord transplant in the U.S. Dr. Wirth went on to serve as the Medical Director for Regenerative Medicine at Geron Corporation where the world's rst clinical trial of human embryonic stem cell (hESC)-derived product occurred which demonstrated initial clinical safety.

Drs. Federoff and Wirth are joined by Dr. Loring, as Chief Scientific Officer; Jay Sial, as Chief Financial Officer; Andres Bratt-Leal, Ph.D., as Vice President of Research and Development; Thorsten Gorba, Ph.D., as Senior Director of Manufacturing and Naveen M. Krishnan, M.D., M.Phil., as Senior Director of Corporate Development.

"Aspen is developing a restorative, disease modifying autologous neuron therapy for people suffering from Parkinson's disease," said Dr. Federoff. "We are fortunate to have such a high-caliber scientific and medical leadership team to make our treatments a reality. Our cell replacement therapy, which originated in the laboratory of Dr. Jeanne Loring and was later supported by Summit for Stem Cell and its President, Ms. Jenifer Raub, has the potential to release dopamine and reconstruct neural networks where no disease-modifying therapies exist."

Aspen's lead product (ANPD001) is currently undergoing investigational new drug (IND)-enabling studies for the treatment of sporadic Parkinson's disease. Aspen is also developing a gene-edited autologous neuron therapy (ANPD002) that is in the research stage and targeted toward familial forms of Parkinson's disease beginning with the most common genetic variant in the gene encoding glucocerebrosidase (GBA). Aspen leverages proprietary machine-learning tools and artificial intelligence to ensure quality control during manufacturing and to deliver a safe and reproducible product for each cell line.

"Aspen's financial backing, combined with its experienced and proven leadership team, positions it well for future success," said Kim P. Kamdar, Ph.D., Partner at Domain Associates, one of Aspen's seed investors. "Domain prides itself on investing in companies that can translate scientific research into innovative medicines and therapies that make a difference in people's lives. We clearly see Aspen as fitting into that category, as it is the only company using a patient's own cells for replacement therapy in Parkinson's disease."

About Aspen Neuroscience

Aspen Neuroscience Inc. is a development stage, private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinson's disease. Aspen's therapies are based upon the scientific work of world-renowned stem cell scientist, Dr. Jeanne Loring, who has developed a novel method for autologous neuron replacement. For more information and important updates, please visithttp://www.aspenneuroscience.com.

CONTACT: Jennifer Viera, AspenNeuroscience@TeamSeismic.com

SOURCE Aspen Neuroscience

http://www.aspenneuroscience.com

Read the rest here:
Aspen Neuroscience Launches With $6.5 Million Seed Funding to Advance First-of-its-Kind Personalized Cell Therapy for Parkinson's Disease - PRNewswire

Spinal Cord Stem Cells Comments Off on Aspen Neuroscience Launches With $6.5 Million Seed Funding to Advance First-of-its-Kind Personalized Cell Therapy for Parkinson’s Disease – PRNewswire | December 14th, 2019

A hockey player paralyzed in the Humboldt Broncos bus crash says it feels good to be home after spending five weeks in Thailand, where he underwent spinal surgery.

It feels good. I mean I felt that cold, cold wind hit my legs, so Im feeling good. Its good to be back, Ryan Straschnitzki said Sunday night as he wheeled himself into the Calgary airport.

The 20-year-old from Airdrie, Alta., who is paralyzed from the chest down, had an epidural stimulator implanted in his spine while he was in Bangkok. A week later, doctors also injected stem cells above and below his spinal injury to try to reverse some of the damage.

Videos posted by Straschnitzki and his father in Thailand show him straightening a leg. In another, Straschnitzki kicks a ball.

In another clip, while hes strapped into a harness, physiotherapists slowly help him walk with a wheeled machine.

It was incredible. I mean the last time I walked beside my dad was before the accident and before I moved away, said Straschnitzki. So doing that again and just seeing the look in his eyes is motivating to me.

Straschnitzki was one of 13 players injured when a semi truck blew through a stop sign and into the path of his junior hockey teams bus at a rural intersection in Saskatchewan in April 2018.

Sixteen others on the bus were killed.

READ MORE: Paralyzed Humboldt Broncos player to get spinal surgery in Thailand

Tom Straschnitzki said hes not an emotional guy, but watching the progress his son made in Thailand has given him hope.

When I actually saw him move his leg, it just took me back to imagining his last steps going onto that bus on that fateful day. And I was just thinking maybe he can go back on the bus one day, he said.

The surgery can cost up to $100,000 but isnt covered by public health care or insurance, because it has not been approved by Health Canada. The Straschnitzkis say theyre frustrated the treatment isnt available here.

Ryan Straschnitzki hopes his experience might at least get the conversation going.

Our health-care system is kind of lacking in this area for spinal cord injuries and I think its huge that Thailand and some other places are getting this started, he said.

I think if Canada can step in and advance this program, I think itll help a lot of people out.

Tom and Michelle Straschnitzki said they have been flooded with comments and questions about their sons procedure.

They want to try it and ask why doesnt Canada do it? I dont have the answer about Canada but they do it in Thailand and it is not experimental, said Tom Straschnitzki.

Health Canada has said it provides licensed spinal cord stimulators but only for pain relief. A spokesman said it has not received an application to have stimulators used to regain motor skills.

READ MORE: Loss for words Injured Bronco shocked, excited over effect of spinal surgery

Ryan Straschnitzki said he isnt expecting a cure but hopes his implant will restore some muscle movement.

Just getting that feeling of being able to move something that I wasnt able to move before and I know core is a huge part of my disability, so anything below my chest is crucial. And after the programming it really helped, he said.

Straschnitzki is hoping to make the Canadian sledge hockey team and compete in the Olympics. He even took his sled with him to Thailand and sat in it as part of his rehabilitation there.

He said he plans to take a few days off before returning to physiotherapy and hitting the ice again back home.

Bill Graveland, The Canadian Press

Like us on Facebook and follow us on Twitter

Continued here:
Kind of lacking: Injured Bronco wonders why Canada wont fund spinal surgery - Houston Today

Spinal Cord Stem Cells Comments Off on Kind of lacking: Injured Bronco wonders why Canada wont fund spinal surgery – Houston Today | December 14th, 2019

Biomedical engineers at Duke University have developed a system that allows for real-time observations of individual cells in the colon of a living mouse.

Researchers expect the procedure to allow new investigations into the digestive systems microbiome as well as the causes of diseases such as inflammatory bowel disease and colon cancer and their treatments.

The procedure described online on December 11 in Nature Communications involves surgically implanting a transparent window into a mouses abdominal skin above the colon. Similar setups are already being used to allow live looks into the detailed inner workings of the brain, spinal cord, liver, lungs and other organs. Imaging a live colon, however, is a slipperier proposition.

A brain doesnt move around a lot, but the colon does, which makes it difficult to get detailed images down to a single cell, said Xiling Shen, the Hawkins Family Associate Professor of Biomedical Engineering at Duke University. Weve developed a magnetic system that is strong enough to stabilize the colon in place during imaging to obtain this level of resolution, but can quickly be turned off to allow the colon to move freely.

Immobilizing the colon for imaging is a tricky task for traditional methods such as glue or stitches. At best they can cause inflammation that would ruin most experiments. At worst they can cause obstructions, which can quickly kill the mouse being studied.

To skirt this issue, Shen developed a magnetic device that looks much like a tiny metal nasal strip and can be safely attached to the colon. A magnetic field snaps the colon into place and keeps it stable during imaging, but once turned off, leaves the colon free to move and function as normal.

A vital organ that houses much of the digestive systems microbiome, the colon can be afflicted by diseases such as inflammatory bowel disease, functional gastrointestinal disorders and cancer. It also plays a key role in regulating the immune system, and can communicate directly with the brain through sacral nerves.

There is a great need to better understand the colon, because it can suffer from so many diseases and plays so many roles with significant health implications, Shen said.

In the study, Shen and his colleagues conducted several proof-of-principle experiments that provide starting points for future lines of research.

The researchers first colonized a living mouse colon with E. coli bacteria, derived from Crohns disease patients, that had been tagged with fluorescent proteins. The researchers then showed they could track the migration, growth and decline of the bacteria for more than three days. This ability could help researchers understand not only how antagonistic bacteria afflict the colon, Shen says, but the positive roles probiotics can play and which strains can best help people with gastrointestinal disorders.

In the next experiment, mice were bred with several types of fluorescent immune cells. The researchers then induced inflammation in the colon and carefully watched the activation of these immune cells. Shen says, this approach could be used with various types of immune cells and diseases to gain a better understanding of how the immune system responds to challenges.

Shen and his colleagues then showed that they could tag and track colon epithelial stem cells associated with colorectal cancer throughout radiation treatment. They also demonstrated that they could watch nerves throughout the colon respond to sacral nerve stimulation, an emerging therapy for treating motility and immune disorders such as functional gastrointestinal disorders and irritable bowel disorder.

While we know electrically stimulating the sacral nerves can alleviate the symptoms of these gastrointestinal disorders, we currently have no idea why or any way to optimize these treatments, Shen said. Being able to see how the colons neurons respond to different waveforms, frequencies and amplitudes of stimulation will be invaluable in making this approach a better option for more patients.

This work was supported by National Institutes of Health (R35GM122465, OT2OD023849), the Defense Advanced Research Projects Agency (N66001-15-2-4059) and the National Cancer Institutes (R35CA197616).

An Intravital Window to Image the Colon in Real Time, Nikolai Rakhilin, Aliesha Garrett, Chi-Yong Eom, Katherine Ramos C., David M. Small, Andrea R. Daniel, Melanie M. Kaelberer, Menansili A. Mejooli, Qiang Huang, Shengli Ding, David G. Kirsch, Diego V. Bohrquez, Nozomi Nishimura, Bradley B. Barth, and Xiling Shen. Nature Communications, 2019. DOI: 10.1038/s41467-019-13699-w

# # #

Read the original post:
A Window into the Hidden World of Colons - Duke Today

Spinal Cord Stem Cells Comments Off on A Window into the Hidden World of Colons – Duke Today | December 14th, 2019

A recent report published by Infinium Global Research on cell therapy market provides in-depth analysis of segments and sub-segments in the global as well as regional cell therapy market.

This press release was orginally distributed by SBWire

Pune, India -- (SBWIRE) -- 12/13/2019 -- The Infinium Global Research analyzes the "Cell Therapy Market (Cell Type - Stem Cell, and Differentiated Cell; Therapy Type - Allogenic Therapies, and Autologous Therapies; Application - Autoimmune Diseases, Oncology, Dermatology, Musculoskeletal Therapies, and Other Applications; End-users - Hospitals and Clinics, Biotechnology and Pharmaceutical Companies, and Research Institutes): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025."

For More Details Get FREE Sample Pages of this Research Report@ https://www.infiniumglobalresearch.com/reports/sample-request/12810

Cell therapy is the transplantation of human cells to replace or repair damaged tissue or cells. With new technologies, products, innovative, and limitless imagination. Cells used for cell therapy often stem cells, cells that can mature into different types of specialized cells. The most common type of cell therapy has been the replacement of mature, functioning cells through blood and platelet transfusions. Cell therapies treat cancer, improving a weakened immune system, autoimmune disease, rebuilding damaged cartilage in joints, urinary problems, and infectious disease, repairing spinal cord injuries, and helping patients with neurological disorders.

Automation in Cell Therapy Manufacturing Providing Intensive Opportunities in the Cell Therapy Market

The rising occurrence of chronic diseases across the globe is the major driver for the growth of the global cell therapy market. Moreover, increasing the geriatric population, increase in cell therapy transplantation rate, and replacement of animal testing model are some of the key factors fueling the market growth. Furthermore, increasing awareness of stem cell therapy and the development of cell banking facilities contributing to the growth of the global cell therapy market.

Moreover, technological advancements and improvements in the regulatory framework continuously provide to the growing market. However, challenges in research and development, lack of proper and advanced healthcare in developing regions may hinder market growth. Furthermore, automation in cell therapy manufacturing providing intensive opportunities in the cell therapy market in the coming years.

Request a Discount on Standard Prices of this Premium Report @ https://www.infiniumglobalresearch.com/reports/request-discount/12810

Stem Cell Therapy is Expected to Hold Maximum Share in the Cell Therapy Market

The global cell therapy market is segmented on the basis of type, therapy, application, and end-user. Types are further segmented into stem cells and differentiated cells. Stem cell therapy is expected to hold maximum share in the cell therapy market. Stem cell therapies having several advantages like regenerating the body organisms and other cells, which contributes to the growth of the stem cell therapies market.

By therapy, the cell therapy market is segmented into allogeneic therapies and autologous therapies. On the basis of application, the market is further divided into autoimmune diseases, oncology, dermatology, musculoskeletal therapies, and other applications. Based on end-users, the market is hospitals and clinics, biotechnology and pharmaceutical companies, and Research Institutes.

North America is Leading the Market Share in the Cell Therapy Market

The cell therapy market is segmented regionally into North America, Europe, Asia-Pacific, and the Rest of the World. North America is leading the market share in the cell therapy market due to the high rate of cancer and blood-related disorders coupled with high investments in the research and development of novel technologies. North America has a firm healthcare organization that acts as an added advantage for the growth of the market in this region.

Asia-Pacific region is anticipated to stimulate the growth of the cell therapy market due to a large number of surgeries performed in this region. Rising awareness about advanced medicinal therapies contributes to the growth of the market in the Asia-Pacific region.

Browse Detailed TOC and Description of this Exclusive Report@ https://www.infiniumglobalresearch.com/healthcare-medical-devices/global-cell-therapy-market

Cell Therapy Market: Competitive Analysis

The leading players in the cell therapy market are NuVasive, Inc., Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., Osiris Therapeutics, Inc., Stemedica Cell Technologies, Inc., MEDIPOST, Stemedica Cell Technologies, Inc., Celgene Corporation, ANTEROGEN.CO., LTD, Vericel Corporation. These companies are adopting strategic partnerships to enhance their product portfolio.

Reasons to Buy this Report:

=> Comprehensive analysis of global as well as regional markets of the cell therapy.

=> Complete coverage of all the product type and application segments to analyze the trends, developments, and forecast of market size up to 2025.

=> Comprehensive analysis of the companies operating in this market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and the latest developments of the company.

=> Infinium Global Research- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

For more information on this press release visit: http://www.sbwire.com/press-releases/automation-in-cell-therapy-manufacturing-is-driving-the-growth-of-the-cell-therapy-market-over-the-forecast-period-2019-2025-1267918.htm

See more here:
Automation in Cell Therapy Manufacturing Is Driving the Growth of the Cell Therapy Market over the Forecast Period (2019-2025) - Press Release -...

Spinal Cord Stem Cells Comments Off on Automation in Cell Therapy Manufacturing Is Driving the Growth of the Cell Therapy Market over the Forecast Period (2019-2025) – Press Release -… | December 14th, 2019

Co-founded by World-Renowned Stem Cell Scientist Jeanne F. Loring, Ph.D. and Andres Bratt-Leal, Ph.D.

Led by Chief Executive Officer Howard Federoff, M.D., Ph.D., Former Vice Chancellor for Health Affairs and Chief Executive Officer of the University of California Irvine Health System

SAN DIEGO, Dec. 12, 2019 /PRNewswire/ -- Aspen Neuroscience, Inc. today announced its launch following a $6.5 million seed round led by Domain Associates and Axon Ventures and including Alexandria Venture Investments,Arch Venture Partners,OrbiMedand Section 32 to develop the first autologous cell therapies for Parkinson's disease. Aspen's proprietary approach was developed by the company's co-founders, Jeanne F. Loring, Ph.D., Professor Emeritus and founding director of the Center for Regenerative Medicine at The Scripps Research Institute, and Andres Bratt-Leal, Ph.D., a former post-doctoral researcher in Dr. Loring's lab. The company was initially supported by Summit for Stem Cell, a founding partner and non-profit organization which provides a variety of services for people with Parkinson's disease. Aspen is led by industry veteran Howard J. Federoff, M.D., Ph.D., as Chief Executive Officer.

Aspen Neuroscience Inc. is a development stage, private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinsons disease. Aspens therapies are based upon the scientific work of world-renowned stem cell scientist, Dr. Jeanne Loring, who has developed a novel method for autologous neuron replacement.

Parkinson's disease is characterized by the loss of specific brain cells that make the chemical dopamine. Without dopamine, nerve cells cannot communicate with muscles and people are left with debilitating motor problems. Aspen is focusing on human pluripotent stem cells, cultured cells that can become any cell type in the human body. The company's research is specific to induced pluripotent stem cells (iPSCs), which it develops by taking a skin biopsy from a person with Parkinson's disease and turning the tissue into pluripotent stem cells using genetic engineering. Aspen then differentiates the pluripotent stem cells into dopamine-releasing neurons that can be transplanted into that same person (autologous), thereby restoring the types of neurons lost in Parkinson's disease.

As an autologous cell therapy for Parkinson's disease, Aspen's treatment would eliminate the need for immunosuppression because the neurons are transplanted back into the same patient from which they were generated. The use of immunosuppression is necessary with currently available cell therapies for Parkinson's disease and when transplanting cells from one patient to another (allogeneic) to prevent rejection but can pre-dispose the patient to life-threatening complications including infection and add cost to the patient and health system. Aspen is the only company in the world offering an autologous neuron replacement therapy for Parkinson's disease.

Aspen encompasses a powerful executive leadership team including Dr. Federoff who, in addition to his leadership roles at the UC Irvine Health System, was the Executive Vice President for Health Sciences and the Executive Dean of Medicine at Georgetown University. Dr. Federoff also has significant biotech industry experience including co-founding MedGenesis Therapeutix and Brain Neurotherapy Bio, as well as leading the U.S. Parkinson's Disease Gene Therapy Study Group. The company is also proud to announce the addition of several experienced and well-known members to its leadership team including Edward Wirth, M.D., Ph.D., as Chief Medical Officer.

Story continues

Dr. Wirth currently serves as the Chief Medical Ofcer for Lineage Cell Therapeutics where he oversees clinical development of its two therapeutic programs for spinal cord injuries and lung cancer. He received his M.D. and Ph.D. from the University of Florida in 1994 and remained to conduct postdoctoral research including leading the University of Florida team that performed the rst human embryonic spinal cord transplant in the U.S. Dr. Wirth went on to serve as the Medical Director for Regenerative Medicine at Geron Corporation where the world's rst clinical trial of human embryonic stem cell (hESC)-derived product occurred which demonstrated initial clinical safety.

Drs. Federoff and Wirth are joined by Dr. Loring, as Chief Scientific Officer; Jay Sial, as Chief Financial Officer; Andres Bratt-Leal, Ph.D., as Vice President of Research and Development; Thorsten Gorba, Ph.D., as Senior Director of Manufacturing and Naveen M. Krishnan, M.D., M.Phil., as Senior Director of Corporate Development.

"Aspen is developing a restorative, disease modifying autologous neuron therapy for people suffering from Parkinson's disease," said Dr. Federoff. "We are fortunate to have such a high-caliber scientific and medical leadership team to make our treatments a reality. Our cell replacement therapy, which originated in the laboratory of Dr. Jeanne Loring and was later supported by Summit for Stem Cell and its President, Ms. Jenifer Raub, has the potential to release dopamine and reconstruct neural networks where no disease-modifying therapies exist."

Aspen's lead product (ANPD001) is currently undergoing investigational new drug (IND)-enabling studies for the treatment of sporadic Parkinson's disease. Aspen is also developing a gene-edited autologous neuron therapy (ANPD002) that is in the research stage and targeted toward familial forms of Parkinson's disease beginning with the most common genetic variant in the gene encoding glucocerebrosidase (GBA). Aspen leverages proprietary machine-learning tools and artificial intelligence to ensure quality control during manufacturing and to deliver a safe and reproducible product for each cell line.

"Aspen's financial backing, combined with its experienced and proven leadership team, positions it well for future success," said Kim P. Kamdar, Ph.D., Partner at Domain Associates, one of Aspen's seed investors. "Domain prides itself on investing in companies that can translate scientific research into innovative medicines and therapies that make a difference in people's lives. We clearly see Aspen as fitting into that category, as it is the only company using a patient's own cells for replacement therapy in Parkinson's disease."

About Aspen Neuroscience

Aspen Neuroscience Inc. is a development stage, private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinson's disease. Aspen's therapies are based upon the scientific work of world-renowned stem cell scientist, Dr. Jeanne Loring, who has developed a novel method for autologous neuron replacement. For more information and important updates, please visithttp://www.aspenneuroscience.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/aspen-neuroscience-launches-with-6-5-million-seed-funding-to-advance-first-of-its-kind-personalized-cell-therapy-for-parkinsons-disease-300973830.html

SOURCE Aspen Neuroscience

Read the original here:
Aspen Neuroscience Launches With $6.5 Million Seed Funding to Advance First-of-its-Kind Personalized Cell Therapy for Parkinson's Disease - Yahoo...

Spinal Cord Stem Cells Comments Off on Aspen Neuroscience Launches With $6.5 Million Seed Funding to Advance First-of-its-Kind Personalized Cell Therapy for Parkinson’s Disease – Yahoo… | December 14th, 2019

Aspen Neuroscience, a new San Diego biotech company working on stem cell treatment for Parkinsons disease, has come out of stealth mode and raised $6.5 million to pursue clinical testing for its therapy.

Co-founded by well-known stem cell scientist Jeanne Loring, Aspen Neuroscience proposes creating stem cells from modified skin cells of Parkinsons patents via genetic engineering.

The stem cells, which can become any type of cell in the body, then would undergo a process that makes them specialize into dopamine-releasing neurons.

People with Parkinsons lose a large number up to 50 percent at diagnosis of specific brain cells that make the chemical dopamine.

Without dopamine, nerve cells cannot communicate with muscles and people are left with debilitating motor problems.

Once these modified skin cells have been engineered to specialize in producing dopamine, they can be transplanted into the Parkinsons patient to restore the types of neurons lost to the disease.

The reason we called it Aspen is because l was raised in the Rocky Mountain states, said Loring. When there is a forest fire in the Rockies, the evergreens are wiped out but the aspens are the fist that regenerate after the burn. So it is a metaphor for regeneration.

Aspen still has a long way to go before its proposed therapy would be available to Parkinsons patients. It has been meeting with the U.S. Food and Drug Administration to provide animal trial data and other information in hopes of getting permission to start human clinical trials.

But the company expects the earliest it would get the go-ahead from FDA to start human trials would be 2021.

Loring has been working on the therapy for eight years. She is professor emeritus and founding director of the Center for Regenerative Medicine at the Scripps Research Institute.

Loring co-founded the 20-employee company with Andres Bratt-Leal, a former post-doctoral researcher in Lorings lab at Scripps.

Joining them as Aspens Chief Executive is Dr. Howard Federoff, former vice chancellor for health affairs and chief executive of the University of California Irvine Health System.

Federoff said the company is the only one pursuing the use of Parkinsons patients own cells as part of neuron replacement therapy.

Aspens proprietary approach does not require the use of immuno-suppression drugs, which can be given when transplanted cells come from another person and perhaps limit the effectiveness of the treatment.

Aspens approach is a therapy that is likely to benefit from the fact that your own cells know how to make the best connections with their own target cells in the brain, even in the setting of Parkinsons disease, said Federoff. So when transplanted it is able to set back the clock on Parkinsons.

In addition to Aspens main therapy, it is researching a gene-editing treatment for forms of Parkinsons common in certain families.

Aspens research work up to now has been supported by Summit for Stem Cell, a non-profit on which provides a variety of services for people with Parkinsons disease.

The new seed funding round was led by Domain Associates and Axon Ventures, with additional participation from Alexandria Venture Investments, Arch Venture Partners, OrbiMed and Section 32.

Aspens financial backing, combined with its experienced and proven leadership team, positions it well for future success, said Kim Kamdar, a partner at Domain Associates. Domain prides itself on investing in companies that can translate scientific research into innovative medicines and therapies that make a difference in peoples lives. We clearly see Aspen as fitting into that category, as it is the only company using a patients own cells for replacement therapy in Parkinsons disease.

See original here:
Aspen Neuroscience gets funding to pursue personalized cell therapy for Parkinsons disease - The San Diego Union-Tribune

Skin Stem Cells Comments Off on Aspen Neuroscience gets funding to pursue personalized cell therapy for Parkinsons disease – The San Diego Union-Tribune | December 14th, 2019